CD8A and neoplasm: Low-dose chemotherapeutics are generally selective for inhibiting MDSCs, which can significantly reduce the number of MDSCs in tumor-bearing mice and enhance tumor-specific CD8+ T cell responses without any significant decrease in other immune cells (Ko et al., 2007; Ishizaki et al., 2011).